Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353026 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Intravenous Artesunate for Solid Tumors
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02353026 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 19 participants.
The verdict
NCT02353026, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase One study to determine the safety, tolerability, and maximum tolerated dose of intravenous artesunate in patients with solid tumors. A rapid dose escalation design will be used, in which single patients will be enrolled to escalating dose levels until a grade 2 or higher toxicity occurs during cycle 1. Enrollment will then continue using 3 to 6 patients at each dose level until a dose is reached at which 2 or more patients out of 6 experience a treatment-related toxicity.
Interventions
- DRUG Intravenous Artesunate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02353026
The ClinicalTrials.gov registry entry for NCT02353026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Artesunate is the first listed.
NCT02353026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02353026 about?
NCT02353026 is a clinical study titled "Phase I Study of Intravenous Artesunate for Solid Tumors". This is a Phase One study to determine the safety, tolerability, and maximum tolerated dose of intravenous artesunate in patients with solid tumors. A rapid dose escalation design will be used, in which single patients will be enrolled to escalating dose levels until a grade 2 or higher toxicity occ...
What is the current status of trial NCT02353026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2015-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02353026?
The interventions under investigation include: Intravenous Artesunate (DRUG).
Who is sponsoring clinical trial NCT02353026?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.